Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study

References

• Fox AD, Maradiaga J, Weiss L, Sanchez J, Starrels JL, Cunningham CO. Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: a qualitative study of the perceptions of former inmates with opioid use disorder. Addict Sci Clin Pract. 2015;10:2. doi:10.1186/s13722-014-0023-025592182
   PubMedGoogle Scholar
• Rudd RA, Aleshire N, Zibbell JE, Gladden M Increases in Drug and Opioid Overdose Deaths — United States, 2000–2014. Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6450a3.htm?s_cid=mm6450a3_w Published 2016 Accessed 1011, 2019.
   Google Scholar
• Vivolo-Kantor AM, Seth P, Gladden RM, et al. Vital signs: trends in emergency department visits for suspected opioid overdoses — United States, July 2016–September 2017. MMWR Morb Mortal Wkly Rep. 2018;67(9):279–285. doi:10.15585/mmwr.mm6709e129518069
   PubMed Web of Science ®Google Scholar
• O’Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving fentanyl, fentanyl analogs, and U-47700 — 10 States, July–December 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197–1202. doi:10.15585/mmwr.mm6643e129095804
   PubMed Web of Science ®Google Scholar
• Jones CM, Logan J, Gladden RM, Bohm MK. Vital signs: demographic and substance use trends among heroin users - United States, 2002–2013. MMWR Morb Mortal Wkly Rep. 2015;64(26):719–725.26158353
   PubMed Web of Science ®Google Scholar
• Peavy KM, Banta-Green CJ, Kingston S, Hanrahan M, Merrill JO, Coffin PO. “Hooked on” prescription-type opiates prior to using heroin: results from a survey of syringe exchange clients. J Psychoactive Drugs. 2012;44(3). doi:10.1080/02791072.2012.704591
   Web of Science ®Google Scholar
• Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600. doi:10.7326/0003-4819-159-9-201311050-0000524189594
   PubMed Web of Science ®Google Scholar
• Merrall ELC, Kariminia A, Binswanger IA, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–1554. doi:10.1111/j.1360-0443.2010.02990.x20579009
   PubMed Web of Science ®Google Scholar
• Clark RE, Samnaliev M, Baxter JD, Leung GY. The evidence doesn’t justify steps by state medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff. 2011;30(8):1425–1433. doi:10.1377/hlthaff.2010.0532
   Web of Science ®Google Scholar
• Tkacz J, Volpicelli J, Un H, Ruetsch C. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abuse Treat. 2014;46(4):456–462. doi:10.1016/j.jsat.2013.10.01424332511
   PubMed Web of Science ®Google Scholar
• Nordlund D, Estee S, Felver S. Methadone and Non-Methadone Treatment of Persons Addicted to Opiates Results in Lower Health Care Costs and Reduced Arrests and Convictions. Olympia, WA: Washington State Department of Social and Health Services; 2004.
   Google Scholar
• Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974–1981. doi:10.1001/jamainternmed.2014.541625347412
   PubMed Web of Science ®Google Scholar
• Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addiction. 2014;109(12):2053–2059. doi:10.1111/add.1268225041346
   PubMed Web of Science ®Google Scholar
• White B, Dore GJ, Lloyd AR, Rawlinson WD, Maher L. Opioid substitution therapy protects against hepatitis C virus acquisition in people who inject drugs: the HITS-c study. Med J Aust. 2014;201(6):326–329. doi:10.5694/mja13.0015325222455
   PubMed Web of Science ®Google Scholar
• MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945. doi:10.1136/bmj.e594523038795
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277–285. doi:10.1016/j.jsat.2009.03.00219339140
   PubMed Web of Science ®Google Scholar
• Lee JD, Nunes EV, Novo P, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–318. doi:10.1016/S0140-6736(17)32812-X29150198
   PubMed Web of Science ®Google Scholar
• Lee JD, Friedmann PD, Kinlock TW, et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016;374(13):1232–1242. doi:10.1056/NEJMoa150540927028913
   PubMed Web of Science ®Google Scholar
• Lee JD, McDonald R, Grossman E, et al. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial. Addiction. 2015;110(6):1008–1014. doi:10.1111/add.1289425703440
   PubMed Web of Science ®Google Scholar
• Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018. doi:10.7326/M17-3107
   Web of Science ®Google Scholar
• Binswanger IA, Whitley E, Haffey P-R, Mueller SR, Min S-J. A patient navigation intervention for drug-involved former prison inmates. Subst Abus. 2015;36(1):34–41. doi:10.1080/08897077.2014.93232024960435
   PubMed Web of Science ®Google Scholar
• Workgroup WSOR. WA State Opioid Response Plan. Olympia 2018 Available from: https://www.doh.wa.gov/Portals/1/Documents/1000/140-182-StateOpioidResponsePlan.pdf Accessed 1011, 2019.
   Google Scholar
• Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi:10.1007/s11606-012-2077-622618581
   PubMed Web of Science ®Google Scholar
• Joosten EAG, de Jong CAJ, de Weert-van Oene GH, Sensky T, van der Staak CPF. Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients. Psychother Psychosom. 2009;78(4):245–253. doi:10.1159/00021952419468259
   PubMed Web of Science ®Google Scholar
• Banta-Green CJ, Von Korff M, Sullivan MD, Merrill JO, Doyle SR, Saunders K. The prescribed opioids difficulties scale: a patient-centered assessment of problems and concerns. Clin J Pain. 2010;26:6. doi:10.1097/AJP.0b013e3181e103d9
   Web of Science ®Google Scholar
• Banta-Green CJ, Coffin PO, Merrill JO, et al. Impacts of an opioid overdose prevention intervention delivered subsequent to acute care. Inj Prev. 2018. injuryprev-2017-042676. doi:10.1136/injuryprev-2017-042676
   Web of Science ®Google Scholar
• Kelly SM, Brown BS, Katz EC, et al. A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients. Am J Drug Alcohol Abuse. 2012;38(3):233–238. doi:10.3109/00952990.2011.64398322242643
   PubMed Web of Science ®Google Scholar
• Schwartz RP, Kelly SM, O’Grady KE, et al. Attitudes toward buprenorphine and methadone among opioid-dependent individuals. Am J Addict. 2008;17(5):396–401. doi:10.1080/1055049080226883518770082
   PubMed Web of Science ®Google Scholar
• Sindicich N, Zador D, Larney S, Dolan K. Patient Motivations, Perceptions and Experiences of Opioid Substitution Therapy in Prison. Technical Report Number 332 Funded by Justice Health and Forensic Mental Health Network. Sydney, Australia: National Drug and Alcohol Research Centre; 2016.
   Google Scholar
• Substance Abuse and Mental Health Services Administration. SAMHSA Opioid Overdose Prevention Toolkit.; 2016 Available from: https://bjatta.bja.ojp.gov/sites/default/files/naloxone/SMA16-4742.pdf Accessed 57, 2018.
   Google Scholar
• Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1–9. doi:10.7326/0003-4819-158-1-201301010-0000323277895
   PubMed Web of Science ®Google Scholar
• Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi:10.1136/bmj.f17423372174
   PubMed Web of Science ®Google Scholar
• Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain—United States, 2016. JAMA. 2016. doi:10.1001/jama.2016.1464
   Web of Science ®Google Scholar
• O’Brien CP, McLellan AT. Myths about the treatment of addiction. Lancet. 1996. doi:10.1016/S0140-6736(96)90409-2
   Web of Science ®Google Scholar
• Cepeda JA, Niccolai LM, Lyubimova A, Kershaw T, Levina O, Heimer R. High-risk behaviors after release from incarceration among people who inject drugs in St. Petersburg, Russia. Drug Alcohol Depend. 2015;147:196–202. doi:10.1016/j.drugalcdep.2014.11.02125496706
   PubMed Web of Science ®Google Scholar
• Binswanger IA, Nowels C, Corsi KF, et al. Return to drug use and overdose after release from prison: a qualitative study of risk and protective factors. Addict Sci Clin Pract. 2012;7(1):3. doi:10.1186/1940-0640-7-322966409
   PubMedGoogle Scholar
• Fox AD, Chamberlain A, Sohler NL, Frost T, Cunningham CO. Illicit buprenorphine use, interest in and access to buprenorphine treatment among syringe exchange participants. J Subst Abuse Treat. 2015;48(1):112–116. doi:10.1016/j.jsat.2014.07.01525205666
   PubMed Web of Science ®Google Scholar
• Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. doi:10.1136/bmj.j155028446428
   PubMed Web of Science ®Google Scholar
• Anton RF, O’Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA. 2006;295(17):2003. doi:10.1001/jama.295.17.200316670409
   PubMed Web of Science ®Google Scholar
• Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT. Developing and implementing a new prison-based buprenorphine treatment program. J Offender Rehabil. 2010;49(2):91–109. doi:10.1080/1050967090353495120473351
   PubMedGoogle Scholar
• Magura S, Lee JD, Hershberger J, et al. Buprenorphine and methadone maintenance in jail and post-release: a randomized clinical trial. Drug Alcohol Depend. 2009;99(1–3):222–230. doi:10.1016/j.drugalcdep.2008.08.00618930603
   PubMed Web of Science ®Google Scholar
• Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405. doi:10.1001/jamapsychiatry.2017.461429450443
   PubMed Web of Science ®Google Scholar